Alivus Life Sciences has entered into Share Purchase cum Subscription Shareholders’ Agreement and Power Supply Agreement with Torrent Urja 19 for consumption and supply of renewable energy (RE). The company will acquire minimum 9.21% stake in Torrent Urja 19.
In addition, the company’s promoter company -- Nirma has also entered into a similar Power Supply Agreement and Share Purchase cum Subscription Shareholders Agreement with Torrent Urja 19 whereby Nirma will acquire minimum 16.99% stake in Torrent Urja 19.
Alivus Life Sciences (Formally known as Glenmark Life Sciences) is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system disease (CNS), pain management and diabetes.
